Clinical Study

Changes of TSH-Stimulation Blocking Antibody (TSBAb) and Thyroid Stimulating Antibody (TSAb) Over 10 Years in 34 TSBAb-Positive Patients with Hypothyroidism and in 98 TSAb-Positive Graves’ Patients with Hyperthyroidism: Reevaluation of TSBAb and TSAb in TSH-Receptor-Antibody (TRAb)-Positive Patients

Figure 2

The clinical course of one of the 2 patients, who initially had TSBAb-positive hypothyroidism and then developed TSAb-positive Graves’ hyperthyroidism (Table 1, Ic). A 45-year-old woman with TSBAb-positive hypothyroidism developed TSAb-positive Graves’ hyperthyroidism. She had TSBAb-positive hypothyroidism ((a), ) with high serum TSH ((b), ∘) and then developed TSAb-positive Graves’ hyperthyroidism ((b), ) with undetectable serum TSH ((b), ∘). TSBAb was dominant initially ((a), ), and then TSAb became dominant ((b), ). TBII (TSH-binding inhibitory immunoglobulin) ((a), ∘) reflects TSBAb- and TSAb-activity. A patient with TSBAb-positive hypothyroidism developed TSAb-positive Graves’ hyperthyroidism. She was treated with T4 and then with MMI.
182176.fig.002a
(a)
182176.fig.002b
(b)